• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由 DAMP 为中心的免疫网络模型预测的 COVID-19 疾病轨迹分化。

Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model.

机构信息

Department of Mathematics, University of Tennessee, Knoxville, TN, United States.

Department of Electrical Engineering & Computer Science, University of Tennessee, Knoxville, TN, United States.

出版信息

Front Immunol. 2021 Oct 28;12:754127. doi: 10.3389/fimmu.2021.754127. eCollection 2021.

DOI:10.3389/fimmu.2021.754127
PMID:34777366
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8582279/
Abstract

COVID-19 presentations range from mild to moderate through severe disease but also manifest with persistent illness or viral recrudescence. We hypothesized that the spectrum of COVID-19 disease manifestations was a consequence of SARS-CoV-2-mediated delay in the pathogen-associated molecular pattern (PAMP) response, including dampened type I interferon signaling, thereby shifting the balance of the immune response to be dominated by damage-associated molecular pattern (DAMP) signaling. To test the hypothesis, we constructed a parsimonious mechanistic mathematical model. After calibration of the model for initial viral load and then by varying a few key parameters, we show that the core model generates four distinct viral load, immune response and associated disease trajectories termed "patient archetypes", whose temporal dynamics are reflected in clinical data from hospitalized COVID-19 patients. The model also accounts for responses to corticosteroid therapy and predicts that vaccine-induced neutralizing antibodies and cellular memory will be protective, including from severe COVID-19 disease. This generalizable modeling framework could be used to analyze protective and pathogenic immune responses to diverse viral infections.

摘要

COVID-19 的表现形式从轻度到中度到重度疾病不等,但也表现为持续的疾病或病毒复发。我们假设 COVID-19 疾病表现的范围是 SARS-CoV-2 介导的病原体相关分子模式(PAMP)反应延迟的结果,包括减弱的 I 型干扰素信号,从而使免疫反应的平衡转向以损伤相关分子模式(DAMP)信号为主导。为了验证这一假设,我们构建了一个简约的机械数学模型。在对初始病毒载量进行模型校准后,然后通过改变几个关键参数,我们表明核心模型产生了四种不同的病毒载量、免疫反应和相关疾病轨迹,称为“患者原型”,其时间动态反映了住院 COVID-19 患者的临床数据。该模型还解释了皮质类固醇治疗的反应,并预测疫苗诱导的中和抗体和细胞记忆将具有保护作用,包括预防严重的 COVID-19 疾病。这种可推广的建模框架可用于分析针对不同病毒感染的保护性和致病性免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/c778fa9cd6fd/fimmu-12-754127-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/30e449c91378/fimmu-12-754127-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/5f853961233b/fimmu-12-754127-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/ab4a933732cb/fimmu-12-754127-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/e018a0648cb8/fimmu-12-754127-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/5e7fe5fa6e98/fimmu-12-754127-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/1b8b4188d1ed/fimmu-12-754127-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/9ede024176e3/fimmu-12-754127-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/8a043ed02bae/fimmu-12-754127-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/836e58b65613/fimmu-12-754127-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/c778fa9cd6fd/fimmu-12-754127-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/30e449c91378/fimmu-12-754127-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/5f853961233b/fimmu-12-754127-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/ab4a933732cb/fimmu-12-754127-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/e018a0648cb8/fimmu-12-754127-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/5e7fe5fa6e98/fimmu-12-754127-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/1b8b4188d1ed/fimmu-12-754127-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/9ede024176e3/fimmu-12-754127-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/8a043ed02bae/fimmu-12-754127-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/836e58b65613/fimmu-12-754127-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ef/8582279/c778fa9cd6fd/fimmu-12-754127-g010.jpg

相似文献

1
Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model.由 DAMP 为中心的免疫网络模型预测的 COVID-19 疾病轨迹分化。
Front Immunol. 2021 Oct 28;12:754127. doi: 10.3389/fimmu.2021.754127. eCollection 2021.
2
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.在单独接受巴利昔单抗或联合接受巴利昔单抗和埃特司韦单抗治疗的 COVID-19 轻症或中症患者中,针对 SARS-CoV-2 的内源性抗体反应。
Front Immunol. 2021 Dec 9;12:790469. doi: 10.3389/fimmu.2021.790469. eCollection 2021.
3
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
4
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.非中和抗体依赖的 SARS-CoV-2 控制与鼻内疫苗诱导的 CD8 T 细胞反应相关。
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
5
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.临床病程对感染后 1 年以上的 SARS-CoV-2 中和抗体的早期动力学、幅度和振幅有影响。
Cell Rep Med. 2022 Jan 24;3(2):100523. doi: 10.1016/j.xcrm.2022.100523. eCollection 2022 Feb 15.
6
Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.COVID-19 患者再次检测到病毒 RNA 阳性时存在低固有免疫和滞后适应性免疫反应。
Front Immunol. 2021 Jul 1;12:664619. doi: 10.3389/fimmu.2021.664619. eCollection 2021.
7
Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation.皮质类固醇治疗 COVID-19 可调节宿主炎症反应和免疫失调的转录特征。
J Leukoc Biol. 2021 Dec;110(6):1225-1239. doi: 10.1002/JLB.4COVA0121-084RR. Epub 2021 Nov 3.
8
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响:一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
9
A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.COVID-19 中单抗的研究进展:在免疫治疗、疫苗开发和病毒检测中的作用。
Hum Antibodies. 2021;29(3):179-191. doi: 10.3233/HAB-200441.
10
Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.轻度 COVID-19 患者和未暴露供体中的免疫记忆揭示了 SARS-CoV-2 感染后持续的 T 细胞反应。
Front Immunol. 2021 Mar 11;12:636768. doi: 10.3389/fimmu.2021.636768. eCollection 2021.

引用本文的文献

1
What's next for computational systems biology?计算系统生物学的下一步是什么?
Front Syst Biol. 2023 Sep 19;3:1250228. doi: 10.3389/fsysb.2023.1250228. eCollection 2023.
2
A multiscale inflammatory map: linking individual stress to societal dysfunction.一张多尺度炎症图谱:将个体压力与社会功能障碍联系起来。
Front Sci. 2024;1. doi: 10.3389/fsci.2023.1239462. Epub 2024 Mar 11.
3
Dynamic heterogeneity in COVID-19: Insights from a mathematical model.COVID-19 的动态异质性:数学模型的启示。

本文引用的文献

1
Dynamically linking influenza virus infection kinetics, lung injury, inflammation, and disease severity.动态关联流感病毒感染动力学、肺损伤、炎症和疾病严重程度。
Elife. 2021 Jul 20;10:e68864. doi: 10.7554/eLife.68864.
2
What is Currently Known About the SARS-CoV2 Variants of Concern.目前对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关注变异株的了解有哪些。
J Epidemiol Glob Health. 2021 Sep;11(3):257-259. doi: 10.2991/jegh.k.210605.001. Epub 2021 Jun 12.
3
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.
PLoS One. 2024 May 31;19(5):e0301780. doi: 10.1371/journal.pone.0301780. eCollection 2024.
4
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review.冠状病毒病(COVID-19)的病理生理学和临床管理:小型综述。
Front Immunol. 2023 Aug 14;14:1116131. doi: 10.3389/fimmu.2023.1116131. eCollection 2023.
5
A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.SARS-CoV-2 免疫的数学模型预测帕罗韦德(paxlovid)反弹。
J Med Virol. 2023 Jun;95(6):e28854. doi: 10.1002/jmv.28854.
6
Towards systems immunology of critical illness at scale: from single cell 'omics to digital twins.迈向规模化的危重症系统免疫学:从单细胞组学到数字孪生。
Trends Immunol. 2023 May;44(5):345-355. doi: 10.1016/j.it.2023.03.004. Epub 2023 Mar 24.
7
Predicting severity in COVID-19 disease using sepsis blood gene expression signatures.利用脓毒症血液基因表达特征预测 COVID-19 疾病的严重程度。
Sci Rep. 2023 Jan 23;13(1):1247. doi: 10.1038/s41598-023-28259-y.
8
Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome.早期肺泡上皮细胞坏死是新冠病毒感染所致急性呼吸窘迫综合征的潜在驱动因素。
iScience. 2023 Jan 20;26(1):105748. doi: 10.1016/j.isci.2022.105748. Epub 2022 Dec 6.
9
Considering innate immune responses in SARS-CoV-2 infection and COVID-19.考虑 SARS-CoV-2 感染和 COVID-19 中的先天免疫反应。
Nat Rev Immunol. 2022 Aug;22(8):465-470. doi: 10.1038/s41577-022-00744-x. Epub 2022 Jul 4.
一种用于比较 SARS-CoV-2、MERS-CoV 和 SARS-CoV 宿主内动力学的定量模型,为 SARS-CoV-2 的发病机制和治疗提供了新的见解。
PLoS Biol. 2021 Mar 22;19(3):e3001128. doi: 10.1371/journal.pbio.3001128. eCollection 2021 Mar.
4
A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness.一种用于上皮组织中急性原发性病毒感染和免疫反应的多尺度、多细胞、时空建模的模块化框架及其在药物治疗时机和有效性方面的应用。
PLoS Comput Biol. 2020 Dec 21;16(12):e1008451. doi: 10.1371/journal.pcbi.1008451. eCollection 2020 Dec.
5
Cytokine Storm.细胞因子风暴
N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.
6
An immune-based biomarker signature is associated with mortality in COVID-19 patients.基于免疫的生物标志物特征与 COVID-19 患者的死亡率相关。
JCI Insight. 2021 Jan 11;6(1):144455. doi: 10.1172/jci.insight.144455.
7
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.神经纤毛蛋白-1 促进 SARS-CoV-2 细胞进入和感染性。
Science. 2020 Nov 13;370(6518):856-860. doi: 10.1126/science.abd2985. Epub 2020 Oct 20.
8
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows.世界卫生组织的试验表明:新冠疫情下,瑞德西韦对存活率几乎没有影响。
BMJ. 2020 Oct 19;371:m4057. doi: 10.1136/bmj.m4057.
9
Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle.肥胖、糖尿病与 COVID-19:一种从东方蔓延而来的传染病,撞上了不健康的西方生活方式所带来的后果。
Front Endocrinol (Lausanne). 2020 Sep 17;11:582870. doi: 10.3389/fendo.2020.582870. eCollection 2020.
10
Long COVID and chronic COVID syndromes.长期新冠和慢性新冠综合征。
J Med Virol. 2021 Mar;93(3):1242-1243. doi: 10.1002/jmv.26587. Epub 2020 Oct 30.